【レポートの概要（一部）】
1 Table of Contents
1 Table of Contents 2
1.1 List of Tables 5
1.2 List of Figures 10
2 Introduction 11
2.1 Inborn Gene or Chromosome Alterations Overview 11
3 Products under Development 12
3.1 Inborn Gene or Chromosome Alterations – Pipeline Products by Stage of Development 12
3.2 Inborn Gene or Chromosome Alterations – Pipeline Products by Territory 13
3.3 Inborn Gene or Chromosome Alterations – Pipeline Products by Regulatory Path 14
3.4 Inborn Gene or Chromosome Alterations – Pipeline Products by Estimated Approval Date 15
3.5 Inborn Gene or Chromosome Alterations – Ongoing Clinical Trials 16
4 Inborn Gene or Chromosome Alterations – Pipeline Products under Development by Companies 17
4.1 Inborn Gene or Chromosome Alterations Companies – Pipeline Products by Stage of Development 17
4.2 Inborn Gene or Chromosome Alterations – Pipeline Products by Stage of Development 20
5 Inborn Gene or Chromosome Alterations Companies and Product Overview 23
5.1 AC-Gen Reading Life S.L. Company Overview 23
5.1.1 AC-Gen Reading Life S.L. Pipeline Products & Ongoing Clinical Trials Overview 23
5.2 Admera Health, LLC Company Overview 24
5.2.1 Admera Health, LLC Pipeline Products & Ongoing Clinical Trials Overview 24
5.3 Agena Bioscience, Inc Company Overview 25
5.3.1 Agena Bioscience, Inc Pipeline Products & Ongoing Clinical Trials Overview 25
5.4 Ariosa Diagnostics, Inc. Company Overview 29
5.4.1 Ariosa Diagnostics, Inc. Pipeline Products & Ongoing Clinical Trials Overview 29
5.5 Atomic International Company Overview 30
5.5.1 Atomic International Pipeline Products & Ongoing Clinical Trials Overview 30
5.6 Baylor College of Medicine Company Overview 31
5.6.1 Baylor College of Medicine Pipeline Products & Ongoing Clinical Trials Overview 31
5.7 BCML GmbH Company Overview 33
5.7.1 BCML GmbH Pipeline Products & Ongoing Clinical Trials Overview 33
5.8 BioCeps (Inactive) Company Overview 34
5.8.1 BioCeps (Inactive) Pipeline Products & Ongoing Clinical Trials Overview 34
5.9 CardioDx, Inc. Company Overview 35
5.9.1 CardioDx, Inc. Pipeline Products & Ongoing Clinical Trials Overview 35
5.10 Celera Corporation Company Overview 37
5.10.1 Celera Corporation Pipeline Products & Ongoing Clinical Trials Overview 37
5.11 Celula, Inc. Company Overview 41
5.11.1 Celula, Inc. Pipeline Products & Ongoing Clinical Trials Overview 41
5.12 Children’s Hospital Boston Company Overview 42
5.12.1 Children’s Hospital Boston Pipeline Products & Ongoing Clinical Trials Overview 42
5.13 China Medical Technologies, Inc. Company Overview 45
5.13.1 China Medical Technologies, Inc. Pipeline Products & Ongoing Clinical Trials Overview 45
5.14 Da An Gene Co., Ltd. Company Overview 48
5.14.1 Da An Gene Co., Ltd. Pipeline Products & Ongoing Clinical Trials Overview 48
5.15 Dana-Farber Cancer Institute, Inc. Company Overview 51
5.15.1 Dana-Farber Cancer Institute, Inc. Pipeline Products & Ongoing Clinical Trials Overview 51
5.16 Epinex Diagnostics Incorporated Company Overview 53
5.16.1 Epinex Diagnostics Incorporated Pipeline Products & Ongoing Clinical Trials Overview 53
5.17 Genentech, Inc. Company Overview 54
5.17.1 Genentech, Inc. Pipeline Products & Ongoing Clinical Trials Overview 54
5.18 German Cancer Research Center Company Overview 55
5.18.1 German Cancer Research Center Pipeline Products & Ongoing Clinical Trials Overview 55
5.19 GILUPI Nanomedizin Company Overview 57
5.19.1 GILUPI Nanomedizin Pipeline Products & Ongoing Clinical Trials Overview 57
5.20 Hadassah Medical Center Company Overview 58
5.20.1 Hadassah Medical Center Pipeline Products & Ongoing Clinical Trials Overview 58
5.21 Helicos BioSciences Corporation Company Overview 59
5.21.1 Helicos BioSciences Corporation Pipeline Products & Ongoing Clinical Trials Overview 59
5.22 Illumina, Inc. Company Overview 60
5.22.1 Illumina, Inc. Pipeline Products & Ongoing Clinical Trials Overview 60
5.23 IntegraGen SA Company Overview 62
5.23.1 IntegraGen SA Pipeline Products & Ongoing Clinical Trials Overview 62
5.24 Interleukin Genetics, Inc. Company Overview 64
5.24.1 Interleukin Genetics, Inc. Pipeline Products & Ongoing Clinical Trials Overview 64
5.25 JS Genetics Inc. Company Overview 66
5.25.1 JS Genetics Inc. Pipeline Products & Ongoing Clinical Trials Overview 66
5.26 Laboratory Corporation of America Holdings Company Overview 67
5.26.1 Laboratory Corporation of America Holdings Pipeline Products & Ongoing Clinical Trials Overview 67
5.27 Laval University Company Overview 69
5.27.1 Laval University Pipeline Products & Ongoing Clinical Trials Overview 69
5.28 LifeCodexx AG Company Overview 70
5.28.1 LifeCodexx AG Pipeline Products & Ongoing Clinical Trials Overview 70
5.29 Maastricht University Medical Center Company Overview 71
5.29.1 Maastricht University Medical Center Pipeline Products & Ongoing Clinical Trials Overview 71
5.30 Massachusetts Eye and Ear Infirmary Company Overview 72
5.30.1 Massachusetts Eye and Ear Infirmary Pipeline Products & Ongoing Clinical Trials Overview 72
5.31 Medical Research Council Company Overview 74
5.31.1 Medical Research Council Pipeline Products & Ongoing Clinical Trials Overview 74
5.32 Micromedic Technologies Ltd Company Overview 75
5.32.1 Micromedic Technologies Ltd Pipeline Products & Ongoing Clinical Trials Overview 75
5.33 Multiplicom N.V. Company Overview 76
5.33.1 Multiplicom N.V. Pipeline Products & Ongoing Clinical Trials Overview 76
5.34 Myriad Genetics, Inc. Company Overview 78
5.34.1 Myriad Genetics, Inc. Pipeline Products & Ongoing Clinical Trials Overview 78
5.35 Natera, Inc. Company Overview 80
5.35.1 Natera, Inc. Pipeline Products & Ongoing Clinical Trials Overview 80
5.36 National University of Singapore Company Overview 85
5.36.1 National University of Singapore Pipeline Products & Ongoing Clinical Trials Overview 85
5.37 NewGene Ltd Company Overview 89
5.37.1 NewGene Ltd Pipeline Products & Ongoing Clinical Trials Overview 89
5.38 NX PharmaGen Inc. Company Overview 94
5.38.1 NX PharmaGen Inc. Pipeline Products & Ongoing Clinical Trials Overview 94
5.39 Paragon Medical, Inc. Company Overview 95
5.39.1 Paragon Medical, Inc. Pipeline Products & Ongoing Clinical Trials Overview 95
5.40 Population Diagnostics Inc. Company Overview 96
5.40.1 Population Diagnostics Inc. Pipeline Products & Ongoing Clinical Trials Overview 96
5.41 Qiagen N.V. Company Overview 100
5.41.1 Qiagen N.V. Pipeline Products & Ongoing Clinical Trials Overview 100
5.42 Quantamerix Company Overview 102
5.42.1 Quantamerix Pipeline Products & Ongoing Clinical Trials Overview 102
5.43 Sapien Biosciences Company Overview 103
5.43.1 Sapien Biosciences Pipeline Products & Ongoing Clinical Trials Overview 103
5.44 Seegene, Inc. Company Overview 104
5.44.1 Seegene, Inc. Pipeline Products & Ongoing Clinical Trials Overview 104
5.45 Sequenom, Inc. Company Overview 106
5.45.1 Sequenom, Inc. Pipeline Products & Ongoing Clinical Trials Overview 106
5.46 Stanford University Company Overview 112
5.46.1 Stanford University Pipeline Products & Ongoing Clinical Trials Overview 112
5.47 The Johns Hopkins University Company Overview 114
5.47.1 The Johns Hopkins University Pipeline Products & Ongoing Clinical Trials Overview 114
5.48 The Sheba Medical Center Company Overview 115
5.48.1 The Sheba Medical Center Pipeline Products & Ongoing Clinical Trials Overview 115
5.49 The University of Utah Company Overview 116
5.49.1 The University of Utah Pipeline Products & Ongoing Clinical Trials Overview 116
5.50 TrovaGene, Inc. Company Overview 117
5.50.1 TrovaGene, Inc. Pipeline Products & Ongoing Clinical Trials Overview 117
5.51 University of Colorado Company Overview 121
5.51.1 University of Colorado Pipeline Products & Ongoing Clinical Trials Overview 121
5.52 University of Washington Company Overview 122
5.52.1 University of Washington Pipeline Products & Ongoing Clinical Trials Overview 122
5.53 VitaPath Genetics, Inc. Company Overview 123
5.53.1 VitaPath Genetics, Inc. Pipeline Products & Ongoing Clinical Trials Overview 123
5.54 Xiamen Zeesan Biotech Co.,Ltd Company Overview 124
5.54.1 Xiamen Zeesan Biotech Co.,Ltd Pipeline Products & Ongoing Clinical Trials Overview 124
5.55 Yale University Company Overview 125
5.55.1 Yale University Pipeline Products & Ongoing Clinical Trials Overview 125
6 Inborn Gene or Chromosome Alterations- Recent Developments 126
7 Appendix 165
7.1 Methodology 165
7.2 About GlobalData 167
7.3 Contact Us 168
7.4 Disclaimer 168
【レポート販売概要】
■ タイトル：世界における先天的遺伝子変異または先天的染色体変異検査製品のパイプライン動向2015■ 英文：Inborn Gene or Chromosome Alterations - Pipeline Review, 2015
■ 発行日：2015年10月1日
■ 調査会社：GlobalData
■ 商品コード：GDME0076EPD
■ 調査対象地域：グローバル
- 世界の民間航空機飛行訓練及びフライトシミュレータ（模擬飛行装置）市場About Civil Aviation Flight Training and Simulation Flight simulator and training systems artificially re-create aircraft flight and the flying environment, thus providing a real flying experience. In civil aviation flight training, such flight simulator systems are mainly used for pilot training. These systems are mainly categorized as full flight simulators (FFS) and flight training devices (FTD …
- 医療部門における人工知能（AI）の世界市場2019-2023Global Artificial Intelligence (AI) Market in Healthcare Sector: About this market Technavio’s artificial intelligence (AI) in healthcare market analysis considers sales from medical imaging and diagnostics, drug discovery, operations management, virtual assistants, and others. Our analysis also considers the sales of artificial intelligence (AI) in the healthcare market in APAC, Europe, North Ame …
- アフリカの自動車用潤滑剤市場：ブランド認知度、市場シェア、販売チャネル分析、市場規模、予測The Africa automotive lubricants market is projected to be worth 763,781.6 kilo liters by 2020, registering a CAGR of 3.5% between 2015 and 2020. The rapid growth in the automotive sector, driven by improved living standards and increased purchasing power of consumers, is a key factor driving the automotive lubricants market in the region. The automotive lubricants market for Africa is classified …
- 世界のNFCチップ市場動向（2014-2018）About NFC Chips Near Field Communication Chips are integrated circuits incorporated in mobile devices and products to store information and to control transactions. NFC chips enable transactions based on NFC technology. In addition, NFC chips enables communication between NFC-enabled devices within a radius of about 4 inches. NFC chips facilitate transaction and data exchange without the need to p …
- 民間航空機用バッテリーの世界市場2016-2020About Commercial Aircraft Battery Aircraft batteries are used to start engines while initiating taxiing or the APU. The batteries are also used to power the airplane interiors and services (such as broadband and air conditioning). The major battery chemistries that are generally used as modern aircraft batteries are lithium-based (Li-ion and lithium iron phosphate), nickel-based (Ni-Cd or nickel m …
- 消化管疾患治療薬（一般用医薬品）の世界市場：胃食道逆流症（GERD）、便秘、下痢、吐気、鼓腸About gastrointestinal OTC drugs OTC drugs are medications that do not require a prescription. In contrast, prescription drugs can be sold only to consumers having a legal prescription. OTC drugs are carefully chosen by regulatory agencies to ensure their safety and efficacy. Gastrointestinal OTC drugs can be bought off-the-shelf. Gastrointestinal OTC drugs are used for indications such as GERD, v …
- Sui Northern Gas Pipelines Limited：石油・ガスバリューチェーン分析レポート2013Sui Northern Gas Pipelines Limited Analysis Across the Oil and Gas Value Chain Report, 2013 Update Summary "Sui Northern Gas Pipelines Limited" Analysis Across the Oil and Gas Value Chain is an essential source for data, analysis and strategic insight into “Sui Northern Gas Pipelines Limited”. The report provides key information relating to oil and gas assets of the company along with its operatio …
- 世界主要国におけるサイクロスポーラ検査市場2015The report presents a detailed analysis of the Cyclospora diagnostics market in the US, Europe (France, Germany, Italy, Spain, UK) and Japan. Current scientific views on the Cyclospora definition, epidemiology and etiology are reviewed. The report provides the 5-year test volume and sales forecasts by country for the following market segments: - Hospitals - Co …
- 無気肺(Atelectasis)：世界の治験レビュー2014年下半期版Atelectasis Global Clinical Trials Review, H2, 2014 Summary GlobalData's clinical trial report, “Atelectasis Global Clinical Trials Review, H2, 2014" provides data on the Atelectasis clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Atelectasis. It includes an overview of the trial numbers and their recruitment status as per the site of …
- 食物繊維の世界市場分析：由来別（全粒粉製品、果物、野菜）、製品別（可溶性、不溶性）、用途別（食品･飲料）、地域別、セグメント予測、2014-2025The global dietary fibers market is expected to reach USD 11.83 billion by 2025, according to a new report by Grand View Research, Inc. Growing functional food & beverage industries are expected to play major roles in the market over the next nine years. Major sources of dietary fibers include whole grains such as brown rice, barley, and whole-wheat, vegetables such as broccoli, and fruits such as …
- アルコール依存症(Alcohol Addiction)：世界の治験レビュー（2015年上半期版）Alcohol Addiction Global Clinical Trials Review, H1, 2015 Summary GlobalData's clinical trial report, “Alcohol Addiction Global Clinical Trials Review, H1, 2015" provides data on the Alcohol Addiction clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Alcohol Addiction. It includes an overview of the trial numbers and their recruitment s …
- アニメ・コレクティブル（収集アイテム）の世界市場2017-2021About Animation CollectiblesAnimation collectibles include licensed merchandise as well as animation toys with characters and properties from feature films and television shows. The merchandise industry, many a times, requires merchandise manufacturers to buy licenses from film or TV production houses. Technavio’s analysts forecast the global animation collectibles market to grow at a CAGR of 4.73 …
- Idemitsu Kosan Co., Ltd.：石油・ガスバリューチェーン分析レポート2013Idemitsu Kosan Co., Ltd. Analysis Across the Oil and Gas Value Chain Report, 2013 Update Summary "Idemitsu Kosan Co., Ltd." Analysis Across the Oil and Gas Value Chain is an essential source for data, analysis and strategic insight into “Idemitsu Kosan Co., Ltd.”. The report provides key information relating to oil and gas assets of the company along with its operations across the value chain. The …
- 緊急流出対応の世界市場予測（～2021）：製品別、サービス別（製品レンタル、廃棄物管理、人材育成）、流出物質別（石油、化学＆危険物）、産業別“The emergency spill response market is driven by stringent environmental regulations for preventing spills and the government focus on reducing the environmental pollution”The emergency spill response market is estimated to reach USD 33.68 billion by 2022, at a CAGR of 7.0% between 2016 and 2022. The market is expected to witness significant growth in the coming years owing to stringent environme …
- 貴重品輸送警備サービスの世界市場About Secure Logistics Secure logistics refer to physical transportation of cash and other valuables from one location to another. It involves guarding and manning high-risk zones such as embassies, airports, and public venues. Cash services and providing security to important venues form the major part of secure logistics. Cash services include a gamut of services such as ATM services, armored ca …
